menopause News
-
The Importance of Diagnosing Osteoporosis in Women
A widespread yet underrated medical condition, Osteoporosis is a bone disease seldom paid importance to in today’s world. In this condition, the bones are porous, meaning they lack density and contain holes – unlike the regular bone structure. This results in the bones becoming brittle and thus susceptible to injury and breakage. A simple fall that may not have been as harmful before ...
By BeamMed Inc.
-
Servomex awarded silver wellbeing at work accolade at first-ever county event
The global expert in gas analysis has been awarded the silver accolade by the East Sussex Wellbeing at Work Programme at the first annual Wellbeing at Work event.It was smiles all-round as Servomex representatives gathered to collect their trophy – the first silver award to be handed to an employer so far within the programme. Servomex was also the first private sector business to achieve the ...
-
Bayer expands development program for elinzanetant with Phase III study in breast cancer patients with vasomotor symptoms caused by endocrine therapy
Study plans to investigate elinzanetant as non-hormonal treatment for vasomotor symptoms caused by endocrine therapy in breast cancer patients Elinzanetant is an innovative non-hormonal development compound in development for the treatment of vasomotor symptoms during menopause Bayer, a global leader in women’s healthcare, announced today that it expands the Phase III clinical ...
By Bayer AG
-
Aresus announces presentation of clincial data for the treatment of female sexual pain with sinecatechins ointment
Aresus Pharma GmbH, a subsidiary of DERMAGO GmbH, announced today that clinical results on the efficacy of 5-10% Topical Sinecatechins (synonyms: “Polyphenon® E“, ”defined extract from green tea leaves“) Ointment for Postmenopausal Vestibulodynia1 were presented at the 2nd Congress on Women’s Health Innovations & Inventions in Tel Aviv on July 11-12th, 2022. ...
-
Mirena approved in Europe for extended duration of use in contraception
Mirena (52mg LNG IUS), Bayer’s long-acting reversible intrauterine system, received regulatory approval in the European Workshare Procedure for up to eight years in contraception, now offering the longest contraceptive duration of use for any hormonal intrauterine system – national approvals expected in Q4 The IUS is one of the most effective birth control methods Mirena was also ...
By Bayer AG
-
New EU research suggests chemicals may increase risk of breast cancer
Breast cancer has increased dramatically in Europe over the past 20 years, with a doubling of the number of cases in some countries over this time period. A recent report presented to the European Parliament suggests that by reducing our exposure to certain chemicals, the number of women who develop breast cancer could also be reduced. The report by UK researchers summarises the evidence for the ...
-
Could Hormone-Related Cancers Start Before Birth?
Much attention has been paid to genetics in breast cancer as disease rates rise, but most women have no family history of the disease, suggesting that there is an environmental risk we don’t yet understand, says environmental health scientist Laura Vandenberg in the School of Public Health and Health Sciences at the University of Massachusetts Amherst. Now she is launching a three-year, ...
-
New phase of breast cancer treatment trial provides fresh hope for patients with incurable disease
Patients with incurable breast cancer could potentially benefit from new Welsh-led research, latest evidence suggests. The research, carried out by Velindre University NHS Trust, in partnership with AstraZeneca and Cardiff University over 10 years was presented at the world renowned American Society of Clinical Oncology conference on 4 June in Chicago and published simultaneously in the ...
By MediWales
-
DSM Announces Receipt of Final Competition Clearance for Acquisition of Martek
Royal DSM N.V. (NYSE Euronext: DSM KON), the global Life Sciences and Materials Sciences company headquartered in the Netherlands, announces today that it has received the unconditional clearance of the Counsel of the National Competition Commission in Spain for its previously announced tender offer for all outstanding shares of common stock of Martek Biosciences Corporation (NASDAQ: MATK) at a ...
-
MagicTouch SCB Granted ‘Breakthrough Device Designation’ for the treatment of Small Coronary Artery Lesions.
Concept Medical Inc. (CMI) has been granted “Breakthrough Device Designation” from the Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) for the MagicTouch SCB Sirolimus Coated Balloon Catheter, for the treatment of small coronary artery lesions in Coronary Artery Disease (CAD). The proposed indication for use includes “The ...
-
RxPONDER Study Results Demonstrate that the Oncotype DX Test Can Now Spare Chemotherapy Use in the Majority of Women with Node-positive Early-stage Breast Cancer
First results from the independent SWOG Cancer Research Network-led Phase III study to be presented at the 2020 San Antonio Breast Cancer Symposium RxPONDER results from over 5,000 women likely to transform the treatment of node-positive breast cancer, as the TAILORx study did in node-negative disease Exact Sciences Corp. (NASDAQ: EXAS) today announced that data from the Rx for Positive ...
-
DSM Successfully Completes Tender Offer for Martek and Expects to Complete Acquisition Today
Royal DSM N.V. (NYSE Euronext: DSM KON), the global Life Sciences and Materials Sciences company, announced today that it has successfully completed the subsequent offering period to its all-cash tender offer to purchase all of the outstanding shares of common stock of Martek Biosciences Corporation at a price of $31.50 per share. The previously announced subsequent offering period expired at ...
-
Why we need to drink hydrogen water and where can i buy hydrogen water
Olansi Healthcare Co., Ltd(Guangzhou Olans Water Treatment Equipments Co. Ltd) is a professional manufacturer in producing hydrogen water products,including hydrogen water maker,hydrogen water machine,hydrogen water filter,hydrogen water generators and hydrogen water bottle.hydrogen water makerIn our life,many people now more focus on their health.like water,many people choose hydrogen water.Does ...
-
Why we need to drink hydrogen water and where can i buy hydrogen water
Olansi Healthcare Co., Ltd(Guangzhou Olans Water Treatment Equipments Co. Ltd) is a professional manufacturer in producing hydrogen water products,including hydrogen water maker,hydrogen water machine,hydrogen water filter,hydrogen water generators and hydrogen water bottle. hydrogen water maker In our life,many people now more focus on their health.like water,many people choose hydrogen ...
-
DSM completes acquisition of Martek; adding new Nutrition growth platform
Royal DSM N.V. (NYSE Euronext: DSM KON), the global Life Sciences and Materials Sciences company, today announces that it has successfully completed the acquisition of Martek Biosciences Corporation. The acquisition, announced on 21 December 2010, is the first major acquisition by DSM after its successful transformation into a Life Sciences and Materials Sciences company. The acquisition, for a ...
-
HEDIS OSW Helps Osteoporosis Patients and Early Detection
Osteoporosis is a disorder that causes the bone density to reduce with time, making bones so weak they get fractured even with a light fall. Regular testing has many benefits as it is tracked by HEDIS (Healthcare Effectiveness Data and Information) to ensure early detection among women to manage their condition properly. Read on to know ...
By BeamMed Inc.
-
S1 Biopharma And Ckd Pharmaceuticals Announce Commercialization Agreement For Lorexys™ In South Korea For Treatment Of Hypoactive Sexual Desire Disorder (Hsdd) In Women
NEW YORK, Dec. 8, 2015 /PRNewswire/ — S1 Biopharma, Inc. a leading developer of first-in-class drugs for the treatment of sexual dysfunction and hypoactive sexual desire disorder (HSDD) in both women and men, and CKD Pharmaceuticals, a leading pharmaceutical company in South Korea, today announced that they have entered into a commercialization agreement for Lorexys™, S1 ...
-
Bayer progressing well with transformation of pharma business and raises peak sales potential of key growth drivers to over twelve billion euros
Strong market uptake of Nubeqa and Kerendia Asundexian projected peak sales of more than five billion euros as treatment option for thrombosis and stroke prevention High-value late-stage development portfolio Positive study outcomes from cell & gene therapy pipeline would provide potential upside Shift of resources enhances commercialization and competitiveness Acquired arm’s ...
By Bayer AG
-
Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX Test
RxPONDER, an independent study led by SWOG Cancer Research Network, demonstrates that guiding treatment with Oncotype DX test can spare chemotherapy use in majority of postmenopausal women Results have already led to updated NCCN Guidelines® for breast cancer New RxPONDER results to be featured in oral presentation at 2021 San Antonio Breast Cancer Symposium (SABCS) Exact Sciences ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you